| scholarly article | Q13442814 |
| meta-analysis | Q815382 |
| P2093 | author name string | Simone Mocellin | |
| Henrik Harling | |||
| Peer Wille-Jørgensen | |||
| Sune Høirup Petersen | |||
| Lene Tschemerinsky Kirkeby | |||
| P2860 | cites work | Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement | Q21562278 |
| Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer | Q24241258 | ||
| Anti-angiogenic therapies for metastatic colorectal cancer | Q24241813 | ||
| Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma | Q24245030 | ||
| The MOS 36-ltem Short-Form Health Survey (SF-36) | Q26778425 | ||
| Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis | Q27860511 | ||
| Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints | Q27860640 | ||
| Quantifying heterogeneity in a meta-analysis | Q27860672 | ||
| Adjuvant chemotherapy with uracil-tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: a multicenter randomized controlled trial | Q28238321 | ||
| Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III | Q28364849 | ||
| Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature | Q29614233 | ||
| The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology | Q29615701 | ||
| Adjuvant therapy with oral fluoropyrimidines as main chemotherapeutic agents after curative resection for colorectal cancer: individual patient data meta-analysis of randomized trials | Q30560218 | ||
| An individual patient data meta-analysis of adjuvant therapy with uracil-tegafur (UFT) in patients with curatively resected rectal cancer. | Q31106341 | ||
| Effective surgical adjuvant therapy for high-risk rectal carcinoma | Q33387384 | ||
| Optimum duration of oral adjuvant chemotherapy of HCFU for colorectal cancer; review of 5-year follow-up | Q34155243 | ||
| Adjuvant treatment of colorectal cancer at the turn of the century: European and US perspectives. | Q34181264 | ||
| Preoperative versus postoperative chemoradiotherapy for rectal cancer | Q34552041 | ||
| Enhanced tumorocidal effect of chemotherapy with preoperative radiotherapy for rectal cancer: preliminary results--EORTC 22921. | Q34559198 | ||
| Chemotherapy with preoperative radiotherapy in rectal cancer | Q34570877 | ||
| Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. | Q34571372 | ||
| Total mesorectal excision in the operative treatment of carcinoma of the rectum | Q34719823 | ||
| Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. | Q34725978 | ||
| Targeted therapy for colorectal cancer: mapping the way. | Q36160087 | ||
| Adjuvant chemotherapy in rectal cancers: why a standard in the US and not in Europe? | Q36303863 | ||
| The integration of oral capecitabine into chemoradiation regimens for locally advanced rectal cancer: how successful have we been? | Q36406297 | ||
| Integration of novel agents into combined-modality treatment for rectal cancer patients | Q36819451 | ||
| UFT (tegafur and uracil) as postoperative adjuvant chemotherapy for solid tumors (carcinoma of the lung, stomach, colon/rectum, and breast): clinical evidence, mechanism of action, and future direction | Q36977683 | ||
| Chemoradiotherapy and adjuvant chemotherapy for rectal cancer | Q37353934 | ||
| Does adjuvant fluoropyrimidine-based chemotherapy provide a benefit for patients with resected rectal cancer who have already received neoadjuvant radiochemotherapy? A systematic review of randomised trials | Q37709739 | ||
| Adjuvant Chemotherapy in Large-Bowel Cancer: Demonstration of Effectiveness of Single Agent Chemotherapy in a Prospectively Controlled, Randomized Trial | Q39556185 | ||
| Adjuvant postoperative radiotherapy and chemotherapy in rectal carcinoma: a review of the Gastrointestinal Tumor Study Group experience | Q39556490 | ||
| Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy | Q39689111 | ||
| Chemotherapy as an adjuvant to surgery for colorectal cancer. A follow-up report | Q40865111 | ||
| Adjuvant therapy in colorectal cancer. (A randomized trial comparing radio-chemotherapy and radio-chemotherapy combined with the methanol extraction residue of BCG, MER) | Q41093181 | ||
| Adjuvant chemoimmuno- and immunotherapy in Dukes' stage B2 and C colorectal carcinoma: a 7-year follow-up analysis | Q42195348 | ||
| Improved overall survival among responders to preoperative chemoradiation for locally advanced rectal cancer | Q43586362 | ||
| Post-operative adjuvant chemotherapy for colorectal cancer with 5-fluorouracil (5-FU) infusion combined with 1-hexylcarbamoyl-5-fluorouracil (HCFU) oral administration after curative resection | Q43930033 | ||
| Efficacy of oral UFT as adjuvant chemotherapy to curative resection of colorectal cancer: multicenter prospective randomized trial | Q43933789 | ||
| Adjuvant therapy in rectal cancer: analysis of stage, sex, and local control--final report of intergroup 0114. | Q43937152 | ||
| Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. | Q44045712 | ||
| Cooperative study of surgical adjuvant chemotherapy for colorectal cancer (third report): five-year results. Cooperative Study Group of Surgical Adjuvant Chemotherapy for Colorectal Cancer in Japan | Q44173641 | ||
| Surgical adjuvant therapy of rectal carcinoma: a controlled evaluation of leucovorin, 5-fluorouracil and radiation therapy with or without interferon-alpha2b | Q44323212 | ||
| A randomized controlled trial of postoperative adjuvant immunochemotherapy for colorectal cancer with oral medicines. | Q44469399 | ||
| Randomised clinical trial of adjuvant postoperative RT vs. sequential postoperative RT plus 5-FU and levamisole in patients with stage II-III resectable rectal cancer: a final report | Q44492279 | ||
| Impact of the introduction and training of total mesorectal excision on recurrence and survival in rectal cancer in The Netherlands | Q44612913 | ||
| Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials | Q44748843 | ||
| Randomized controlled trial of the efficacy of adjuvant immunochemotherapy and adjuvant chemotherapy for colorectal cancer, using different combinations of the intracutaneous streptococcal preparation OK-432 and the oral pyrimidines 1-hexylcarbamoyl | Q44859969 | ||
| The diagnosis and management of rectal cancer: expert discussion and recommendations derived from the 9th World Congress on Gastrointestinal Cancer, Barcelona, 2007. | Q45083133 | ||
| Chemoradiotherapy for rectal cancer--when, why, and how? | Q45117142 | ||
| Randomized, controlled study of continuous 5-FU infusion starting immediately after curative surgery for advanced colorectal cancer. | Q46005950 | ||
| Neoadjuvant capecitabine combined with standard radiotherapy in patients with locally advanced rectal cancer: mature results of a phase II trial | Q46240824 | ||
| Preoperative concurrent radiotherapy with capecitabine before total mesorectal excision in locally advanced rectal cancer | Q46507603 | ||
| cT3N0 rectal cancer: potential overtreatment with preoperative chemoradiotherapy is warranted. | Q46803172 | ||
| Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the Nordic Gastrointestinal Tumour Adjuvant Therapy Group | Q46839370 | ||
| Randomized phase II study of neoadjuvant combined-modality chemoradiation for distal rectal cancer: Radiation Therapy Oncology Group Trial 0012. | Q46919095 | ||
| Patients with curative resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy: does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the European Organisation for Research and Treatment of Canc | Q46974069 | ||
| Prognostic factors of colorectal cancer. Results of multivariate analysis of curative resection cases with or without adjuvant chemotherapy. | Q51027002 | ||
| Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer. | Q51801469 | ||
| A prospective randomized trial comparing intravenous 5-fluorouracil and oral doxifluridine as postoperative adjuvant treatment for advanced rectal cancer. | Q53510486 | ||
| Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum (Kanagawa). | Q55043570 | ||
| Radiation therapy and fluorouracil with or without semustine for the treatment of patients with surgical adjuvant adenocarcinoma of the rectum. Gastrointestinal Tumor Study Group | Q60357949 | ||
| Postoperative adjuvant chemotherapy or radiation therapy for rectal cancer: results from NSABP protocol R-01 | Q68125681 | ||
| NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer | Q68536918 | ||
| Adjuvant chemotherapy with 5-fluorouracil, vincristine and CCNU for patients with Dukes' C colorectal cancer. The Swedish Gastrointestinal Tumour Adjuvant Therapy Group | Q68657743 | ||
| Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma | Q68702101 | ||
| Prolongation of the disease-free interval in surgically treated rectal carcinoma | Q69861242 | ||
| Results of Postoperative Treatment of Colorectal Cancer by Radiotherapy, Chemotherapy and Immunotherapy | Q70776007 | ||
| Postoperative chemotherapy for colorectal cancer by combining 5-fluorouracil infusion and 1-hexylcarbamoyl-5-fluorouracil administration after curative resection | Q71079641 | ||
| A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer | Q71198607 | ||
| Oral adjuvant chemotherapy with carmofur (HCFU) for colorectal cancer: five-year follow-up. Tokai HCFU Study Group--third study on colorectal cancer | Q71720705 | ||
| Five-year results of a randomized controlled trial of adjuvant chemotherapy for curatively resected colorectal carcinoma. The Colorectal Cancer Chemotherapy Study Group of Japan | Q71833709 | ||
| Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery | Q72084377 | ||
| Adjuvant Chemotherapy in Cancer of the Colon and Rectum: Demonstration of Effectiveness of Prolonged 5-FU Chemotherapy in a Prospectively Controlled, Randomized Trial | Q72653039 | ||
| Improved survival with preoperative radiotherapy in resectable rectal cancer | Q73199939 | ||
| Adjuvant postoperative fluorouracil-modulated chemotherapy combined with pelvic radiation therapy for rectal cancer: initial results of intergroup 0114 | Q73368695 | ||
| Randomized trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02 | Q73502403 | ||
| Importance of 5-fluorouracil dose-intensity in a double randomised trial on adjuvant portal and systemic chemotherapy for Dukes B2 and C colorectal cancer | Q73505292 | ||
| Randomized controlled trial of postoperative radiotherapy and short-term time-scheduled 5-fluorouracil against surgery alone in the treatment of Dukes B and C rectal cancer. Norwegian Adjuvant Rectal Cancer Project Group | Q73649185 | ||
| [Prospective controlled study on the usefulness of Carmofur as a postoperative adjuvant chemotherapy for colorectal cancer] | Q73830619 | ||
| Postoperative adjuvant chemotherapy with 1-hexylcarbamoyl-5-fluorouracil in patients with colorectal cancer and at a high risk for recurrence | Q77802635 | ||
| Postoperative radiation and concomitant bolus fluorouracil with or without additional chemotherapy with fluorouracil and high-dose leucovorin in patients with high-risk rectal cancer: a randomized phase III study conducted by the Hellenic Cooperativ | Q78111187 | ||
| Adjuvant treatment of colorectal cancer | Q80346392 | ||
| Postoperative chemotherapy may not be necessary for patients with ypN0-category after neoadjuvant chemoradiotherapy of rectal cancer | Q83940060 | ||
| Final results of randomized trials by the National Surgical Adjuvant Study of Colorectal Cancer (NSAS-CC) | Q84275106 | ||
| Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q84424073 | ||
| P433 | issue | 3 | |
| P921 | main subject | chemotherapy | Q974135 |
| P304 | page(s) | CD004078 | |
| P577 | publication date | 2012-03-14 | |
| P1433 | published in | Cochrane Database of Systematic Reviews | Q15750361 |
| P1476 | title | Postoperative adjuvant chemotherapy in rectal cancer operated for cure |
| Q33647636 | A Phase II/III randomized controlled trial comparing perioperative versus postoperative chemotherapy with mFOLFOX6 for lower rectal cancer with suspected lateral pelvic node metastasis: Japan Clinical Oncology Group Study JCOG1310 (PRECIOUS study) |
| Q94397021 | A Text-Mining Framework for Supporting Systematic Reviews |
| Q53625889 | A minimum yield of twelve lymph nodes in rectal cancer remains valid in the era of neo-adjuvant treatment : results from a national cohort study. |
| Q38272671 | A systematic review and meta-analysis of adjuvant chemotherapy after neoadjuvant treatment and surgery for rectal cancer |
| Q52576594 | Adjuvant Chemotherapy Seemed Not to Have Survival Benefit in Rectal Cancer Patients with ypTis-2N0 After Preoperative Radiotherapy and Surgery from a Population-Based Propensity Score Analysis. |
| Q33698724 | Adjuvant chemotherapy |
| Q30884451 | Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data |
| Q85274838 | Adjuvant chemotherapy for patients with rectal cancer? |
| Q47205433 | Adjuvant chemotherapy for patients with ypT0-2N0-category after neoadjuvant chemoradiotherapy for rectal cancer |
| Q26775099 | Adjuvant chemotherapy for rectal cancer: Is it needed? |
| Q94527011 | Adjuvant chemotherapy in curatively resected rectal cancer: How valid are the data? |
| Q37119089 | Adjuvant chemotherapy in rectal cancer: defining subgroups who may benefit after neoadjuvant chemoradiation and resection: a pooled analysis of 3,313 patients |
| Q35758360 | Adjuvant therapy decisions based on magnetic resonance imaging of extramural venous invasion and other prognostic factors in colorectal cancer |
| Q40481695 | Adjuvant treatment for resected rectal cancer: impact of standard and intensified postoperative chemotherapy on disease-free survival in patients undergoing preoperative chemoradiation-a propensity score-matched analysis of an observational database |
| Q87164240 | Adjuvant vs.salvage radiotherapy for patients at high risk for recurrence after radical prostatectomy |
| Q36025983 | Advances and challenges in treatment of locally advanced rectal cancer |
| Q36164285 | Adverse Effects of Anastomotic Leakage on Local Recurrence and Survival After Curative Anterior Resection for Rectal Cancer: A Systematic Review and Meta-analysis |
| Q38739164 | Annual hazard rate of relapse of stage II and III colorectal cancer after primary therapy |
| Q38216007 | Bevacizumab in the pre-operative treatment of locally advanced rectal cancer: a systematic review. |
| Q98159773 | Challenges and shifting treatment strategies in the surgical treatment of locally advanced rectal cancer |
| Q89459268 | Changes in fatigue in rectal cancer patients before and after therapy: a systematic review and meta-analysis |
| Q36394634 | Characteristics affecting survival after locally advanced colorectal cancer in Quebec |
| Q33735234 | Colorectal cancer: from prevention to personalized medicine. |
| Q36913615 | Comparative effectiveness of postoperative chemotherapy among older patients with non-metastatic rectal cancer treated with preoperative chemoradiotherapy |
| Q55403954 | Comparisons of Efficacy, Safety, and Cost of Chemotherapy Regimens FOLFOX4 and FOLFIRINOX in Rectal Cancer: A Randomized, Multicenter Study. |
| Q35445092 | Consensus statement: the 16th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Saskatoon, Saskatchewan; September 5-6, 2014 |
| Q89497708 | Controversies in the Management of Lateral Pelvic Lymph Nodes in Patients With Advanced Rectal Cancer: East or West? |
| Q38691264 | Controversies in the multimodality management of locally advanced rectal cancer |
| Q28072948 | Current debate in the oncologic management of rectal cancer |
| Q57088752 | EMVI-positive stage II rectal cancer has similar clinical outcomes as stage III disease following pre-operative chemoradiotherapy |
| Q35709494 | Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer |
| Q34659103 | Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study |
| Q34538305 | Folate levels measured by LC-MS/MS in patients with colorectal cancer treated with different leucovorin dosages |
| Q37695253 | Future directions for the early detection of colorectal cancer recurrence |
| Q36250681 | High preoperative serum globulin in rectal cancer treated with neoadjunctive chemoradiation therapy is a risk factor for poor outcome |
| Q89502186 | Impact of Adjuvant Therapy Type on Survival in Stage II/III Rectal Cancer Without Preoperative Chemoradiation: A Korean Multicenter Retrospective Study |
| Q38207015 | Interval to surgery after neoadjuvant treatment for colorectal cancer |
| Q92560006 | Intraoperative radiotherapy as an immediate adjuvant treatment of rectal cancer due to limited access to external-beam radiotherapy |
| Q31023316 | Is Chemotherapy or Radiation Therapy in Addition to Surgery Beneficial for Locally Advanced Rectal Cancer in the Elderly? A National Cancer Data Base (NCDB) Study. |
| Q50014081 | Laparoscopic liver resection for colorectal liver metastasis patients allows patients to start adjuvant chemotherapy without delay: a propensity score analysis |
| Q38100653 | Modern rectal cancer multidisciplinary treatment: the role of radiation and surgery |
| Q92665182 | Monthly tegafur-uracil maintenance for increasing relapse-free survival in ypStage III rectal cancer patients after preoperative radiotherapy, radical resection, and 12 postoperative chemotherapy cycles: a retrospective study |
| Q34537462 | Multimodal therapy in treatment of rectal cancer is associated with improved survival and reduced local recurrence - a retrospective analysis over two decades |
| Q49564059 | Neoadjuvant Strategies: Locally Advanced Rectal Cancer |
| Q39172475 | Neoadjuvant Treatment for Locally Advanced Rectal Cancer: New Concepts in Clinical Trial Design |
| Q60927250 | Novelties in treatment of locally advanced rectal cancer |
| Q98165409 | Omission of Adjuvant Chemotherapy in Rectal Cancer Patients with Pathologic Complete Response: a National Analysis |
| Q37715201 | On a prolonged interval between rectal cancer (chemo)radiotherapy and surgery |
| Q64274403 | Organ Preservation Strategies After Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer |
| Q55121878 | Outcomes prediction in pre-operative radiotherapy locally advanced rectal cancer: leucocyte assessment as immune biomarker. |
| Q33417569 | Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial |
| Q60919179 | Pathological nodal staging score for rectal cancer patients treated with radical surgery with or without neoadjuvant therapy: a postoperative decision tool |
| Q36824126 | Patterns of Colorectal Cancer Care in the United States: 1990-2010. |
| Q57297260 | Peroxiredoxins in Colorectal Cancer: Predictive Biomarkers of Radiation Response and Therapeutic Targets to Increase Radiation Sensitivity? |
| Q37564794 | Possible contribution of IMRT in postoperative radiochemotherapy for rectal cancer: analysis on 1798 patients by prediction model. |
| Q94336862 | Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma |
| Q37672022 | Pre- and post-surgery treatments in rectal cancer: a long-term single-centre experience |
| Q57035666 | Preoperative radiotherapy and curative surgery for the management of localised rectal carcinoma |
| Q36315147 | Prognostic Effect of Ultra-Staging Node-Negative Colon Cancer Without Adjuvant Chemotherapy: A Prospective National Cancer Institute-Sponsored Clinical Trial |
| Q34110610 | Prognostic nomograms for predicting survival and distant metastases in locally advanced rectal cancers |
| Q42321597 | Prognostic significance of survivin in rectal cancer patients treated with surgery and postoperative concurrent chemo-radiation therapy |
| Q39554319 | Progress in rectal cancer treatment. |
| Q38973703 | Rectal cancer patients after neoadjuvant radiotherapy (30Gy/10f) with negative lymph node may not benefit from postoperative adjuvant chemotherapy: a retrospective study |
| Q27021105 | Review of systemic therapies for locally advanced and metastatic rectal cancer |
| Q41594853 | Role of adjuvant chemotherapy in locally advanced rectal cancer with ypT0-3N0 after preoperative chemoradiation therapy and surgery. |
| Q92713073 | Short-course or long-course radiation therapy as a part of a neoadjuvant regimen for stage II & III rectal adenocarcinoma? |
| Q34761643 | Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer--the RAPIDO trial |
| Q28084403 | Systematic Review: Adjuvant Chemotherapy for Locally Advanced Rectal Cancer with respect to Stage of Disease |
| Q57455374 | Systematic review of treatment intensification using novel agents for chemoradiotherapy in rectal cancer |
| Q54114270 | Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer. |
| Q33574744 | Tailored Treatment of Colorectal Cancer: Surgical, Molecular, and Genetic Considerations |
| Q41873145 | The Efficacy of Adjuvant Chemotherapy in Patients With Stage II/III Resected Rectal Cancer Treated With Neoadjuvant Chemoradiation Therapy |
| Q49564131 | The Perfect Total Mesorectal Excision Obviates the Need for Anything Else in the Management of Most Rectal Cancers |
| Q33851067 | The effect of geriatric intervention in frail elderly patients receiving chemotherapy for colorectal cancer: a randomized trial (GERICO). |
| Q34234935 | The emerging role of neoadjuvant chemotherapy for rectal cancer |
| Q41245313 | The influence of neoadjuvant therapy for the prognosis in patients with rectal carcinoma: a retrospective study |
| Q86633285 | The paradox of preoperative (chemo)radiotherapy for rectal cancer |
| Q89467728 | The potential benefit of adjuvant chemotherapy in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy is not predicted by tumor regression grade |
| Q92189101 | Total neoadjuvant therapy in locally advanced rectal cancer: Role of systemic chemotherapy |
| Q34505944 | Tumor phosphatidylinositol-3-kinase signaling and development of metastatic disease in locally advanced rectal cancer |
| Q38692803 | Update on advances and controversy in rectal cancer treatment |
| Q36562267 | YpT1-2N0 rectal cancer after neoadjuvant chemoradiation has lower survival compared with pT1-2N0 rectal cancer |
Search more.